Stoke Therapeutics (NASDAQ:STOK) versus MannKind (NASDAQ:MNKD) Head-To-Head Comparison

MannKind (NASDAQ:MNKD) and Stoke Therapeutics (NASDAQ:STOK) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their institutional ownership, earnings, profitability, analyst recommendations, dividends, valuation and risk.

Institutional & Insider Ownership

49.5% of MannKind shares are owned by institutional investors. 2.6% of MannKind shares are owned by company insiders. Comparatively, 9.6% of Stoke Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings for MannKind and Stoke Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MannKind	1	2	8	0	2.64
Stoke Therapeutics	1	0	10	0	2.82

MannKind presently has a consensus target price of $8.33, indicating a potential upside of 98.89%. Stoke Therapeutics has a consensus target price of $44.17, indicating a potential upside of 59.39%. Given MannKind’s higher possible upside, equities analysts plainly believe MannKind is more favorable than Stoke Therapeutics.

Profitability

This table compares MannKind and Stoke Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MannKind	-11.08%	N/A	-6.31%
Stoke Therapeutics	-862.07%	-67.30%	-58.52%

Risk & Volatility

MannKind has a beta of 1.1, suggesting that its share price is 10% more volatile than the S&P 500. Comparatively, Stoke Therapeutics has a beta of 1.36, suggesting that its share price is 36% more volatile than the S&P 500.

Earnings and Valuation

This table compares MannKind and Stoke Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MannKind	$348.97 million	3.86	$5.86 million	($0.23)	-18.22
Stoke Therapeutics	$184.42 million	9.83	-$6.89 million	($3.77)	-7.35

MannKind has higher revenue and earnings than Stoke Therapeutics. MannKind is trading at a lower price-to-earnings ratio than Stoke Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

MannKind beats Stoke Therapeutics on 8 of the 13 factors compared between the two stocks.

About MannKind

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

About Stoke Therapeutics

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.